Atea Pharmaceuticals (AVIR) Net Income towards Common Stockholders: 2019-2024
Historic Net Income towards Common Stockholders for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$168.4 million.
- Atea Pharmaceuticals' Net Income towards Common Stockholders fell 129.40% to -$34.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$115.9 million, marking a year-over-year decrease of 195.64%. This contributed to the annual value of -$168.4 million for FY2024, which is 23.85% down from last year.
- As of FY2024, Atea Pharmaceuticals' Net Income towards Common Stockholders stood at -$168.4 million, which was down 23.85% from -$136.0 million recorded in FY2023.
- Atea Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $121.2 million for FY2021, and its period low was -$168.4 million during FY2024.
- Over the past 3 years, Atea Pharmaceuticals' median Net Income towards Common Stockholders value was -$136.0 million (recorded in 2023), while the average stood at -$140.1 million.
- As far as peak fluctuations go, Atea Pharmaceuticals' Net Income towards Common Stockholders surged by 1,207.06% in 2021, and later plummeted by 195.64% in 2022.
- Over the past 5 years, Atea Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$10.9 million in 2020, then spiked by 1,207.06% to $121.2 million in 2021, then slumped by 195.64% to -$115.9 million in 2022, then dropped by 17.30% to -$136.0 million in 2023, then declined by 23.85% to -$168.4 million in 2024.